Ambry Genetics RainDance's New ThunderStorm™ System for High-Throughput Next-Generation Targeted Sequencing Services

September 20, 2011

FOR IMMEDIATE RELEASE

Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656

LEXINGTON, Mass., - September 20, 2011 – RainDance Technologies, Inc., the Digital Biology™ company, today announced that Ambry Genetics has purchased the company's new ThunderStorm™ System for genetic testing and next-generation targeted sequencing services. Launching next month, RainDance's ThunderStorm System is a fully-automated and walkaway high-throughput targeted sequencing solution that enables researchers to process 96 samples per day on a proven platform that generates higher-quality data faster than ever before.

"We are excited to add this state-of-the-art high-throughput targeted sequencing technology to our laboratory," said Ardy Arianpour, Vice President of Business Development at Ambry Genetics. "The RainDance ThunderStorm System is a true game changer both in terms of processing speed and data quality, and we look forward to rolling out a portfolio of services based on this technology platform to our customers."

 

"As more genetic variations are linked to human health and catastrophic diseases like cancer, researchers require higher throughput validation solutions that allow for the rapid, high-resolution analysis of specific genes of interest," said Andy Watson, Chief Marketing Officer at RainDance Technologies. "Our ThunderStorm System is a cost-effective solution that enables the comprehensive interrogation and accurate classification of all variation contained in any region of the genome with increased accuracy, greater uniformity and more complete coverage than any other sequence enrichment method."

 

Utilizing RainDance's proprietary microdroplet-based technology, the ThunderStorm System simultaneously processes millions of individual single molecule PCR reactions by encapsulating each reaction in separate aqueous droplets. The system supports a range of targeted sequencing applications including: candidate gene lists, regions of association, signaling pathways and deep sequencing of heterogeneous tumor samples.

 

RainDance Technologies will be unveiling the ThunderStorm System at the upcoming International Congress of Human Genetics Conference in Montreal, Canada, October 11 – 15. For more information please visit RainDanceTech.com/ashg2011.

 

For more information about RainDance Technologies, please visit RainDanceTech.com. For more information about Ambry Genetics, please visit AmbryGen.com.


About RainDance Technologies

RainDance Technologies is pioneering the use of high-throughput microdroplet-based analysis in human health and life science research. The company's core RainStorm™ technology generates millions of discrete droplets that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The power, precision and simplicity of microdroplets enable researchers to answer complex questions with unprecedented sensitivity and quantitation. The complete RainDance solution includes automated instrumentation, customizable bioinformatics and high-value consumables and reagents for applications including targeted next-generation DNA sequencing, methylation, digital PCR and single cell analysis. Based in Lexington, Massachusetts, the company supports scientists around the world through its international sales and support operations and a global network of distributors and service providers. For more information, please visit www.RainDanceTech.com.

About Ambry Genetics ®

Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.

Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com

Search Results

Start your search...